Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 7 May 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's share capital as of 30 April 2024. The report shows that the company's regulary/registered share capital and issued shares did not decrease during the month, with the regulary/registered share capital deposited at 5,000,000,000 shares with a face value of $0.00001, and the total remained at $50,000. In addition, under the Initial Public Offering Option Plan adopted on June 28, 2022, the change in stock options during the month included the expiry of 14,000 share options, bringing the number of stock options outstanding at the end of the month to 436,000. The Company confirms that all securities issued this month have received formal authorization from the Board of Directors and meet the requirements of the relevant Listing Rules.

Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 7 May 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's share capital as of 30 April 2024. The report shows that the company's regulary/registered share capital and issued shares did not decrease during the month, with the regulary/registered share capital deposited at 5,000,000,000 shares with a face value of $0.00001, and the total remained at $50,000. In addition, under the Initial Public Offering Option Plan adopted on June 28, 2022, the change in stock options during the month included the expiry of 14,000 share options, bringing the number of stock options outstanding at the end of the month to 436,000. The Company confirms that all securities issued this month have received formal authorization from the Board of Directors and meet the requirements of the relevant Listing Rules.